Diaceutics, London Genetics to Co-Develop Software to Support Biomarker Research Collaborations

The new software, which the firms plan to launch next year, is based on the Diaceutics Fusion platform, a personalized medicine planning application designed for targeted therapy development teams, and the London Genetics Biomarker Pathway platform.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.